REDWOOD CITY, Calif. – January 7, 2013 – Proteus Digital Health Inc. announced today the expansion of the company’s executive team and board of directors with the addition of three healthcare leaders to drive its commercial strategy as the company launches its first digital health products. The announcement was made at the 2013 JP Morgan Healthcare Conference in San Francisco, Calif.
Source: Reuters.com
SAN JOSE, Calif. and HERZLIYA, Israel, April 26, 2012 (GLOBE NEWSWIRE) — Myrtle Potter & Company announced today that it has been retained by IMMUNE Pharmaceuticals as an advisor for their NanomAb Antibody Drug Conjugate product portfolio. Myrtle Potter & Company is the advisory firm of Myrtle Potter, former COO and president of Commercial Operations at Genentech. As part of the collaboration, Myrtle Potter & Company has engaged Suzy Jones, who is currently managing partner of DNA Ink and formerly headed business development at Genentech. Suzy Jones will assume the role of Chief Business Development Officer at IMMUNE.